Seeking Alpha

Amarin (AMRN) -6.8% after saying that doesn't expect a decision from the FDA this month on...

Amarin (AMRN) -6.8% after saying that doesn't expect a decision from the FDA this month on whether to grant the company's request for five-year marketing exclusivity for its Vascepa heart pill, which the agency approved in July. Amarin doesn't haven't a clue whether the FDA will grant its request or when it will make a decision.
From other sites
Comments (3)
  • Donegal17
    , contributor
    Comments (2) | Send Message
     
    I'm a Sr.Acct.Exec. at a Radio Station in Maryland. I thought when a

     

    new Drug got approved by the FDA, that it received Patent protection

     

    for over 10 years, I don't understand the request for five-year marketing exclusivity
    10 Oct 2012, 10:22 AM Reply Like
  • see punjabi
    , contributor
    Comments (363) | Send Message
     
    It's not 10 years, its' 5 years.
    10 Oct 2012, 11:50 AM Reply Like
  • bobberger
    , contributor
    Comments (2) | Send Message
     
    I'm an investor in AMRN and am convinced that if the FDA is continuing to consider NCE status instead of just saying no, that they are extremely close to yes rather than no. They don't delay an outcome this long if they aren't very close to an approval.
    10 Oct 2012, 12:52 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs